Biogen (BIIB)
(Delayed Data from NSDQ)
$215.63 USD
-0.71 (-0.33%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $215.00 -0.63 (-0.29%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Biogen Inc. (BIIB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$299.78 | $364.00 | $240.00 | 39.03% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for Biogen Inc. comes to $299.78. The forecasts range from a low of $240.00 to a high of $364.00. The average price target represents an increase of 39.03% from the last closing price of $215.63.
Analyst Price Targets (27)
Broker Rating
Biogen Inc. currently has an average brokerage recommendation (ABR) of 1.66 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 32 brokerage firms. The current ABR compares to an ABR of 1.66 a month ago based on 32 recommendations.
Of the 32 recommendations deriving the current ABR, 20 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 62.5% and 9.38% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 9.38%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 20 | 20 | 20 | 21 | 22 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 9 | 9 | 9 | 8 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.66 | 1.66 | 1.66 | 1.59 | 1.48 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/4/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/20/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
2/20/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
2/14/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
2/14/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
2/14/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
2/14/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/14/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
2/14/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
2/12/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
1/10/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Not Available | Hold |
12/7/2023 | Not Identified | Not Identified | Hold | Moderate Buy |
11/8/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
5/11/2023 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
5/1/2023 | Guggenheim Securities | Yatin Suneja | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.66 |
ABR (Last week) | 1.66 |
# of Recs in ABR | 32 |
Average Target Price | $299.78 |
LT Growth Rate | 7.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 3.48 |